Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: () Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier


Rating: Volatility:
Total Grade: Industry:

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company sells metformin hydrochloride extended release tablets under the Glumetza name and bromocriptine mesylate tablets under the CYCLOSET name, which are indicated to treat type 2 diabetes; and omeprazole/sodium bicarbonate capsules and powder for oral suspension under the Zegerid name primarily to pharmaceutical wholesale distributors. Its products under development include Budesonide MMX, which completed two Phase III clinical studies for the treatment of ulcerative colitis; Rhucin (recombinant human C1 inhibitor) under Phase IIIb clinical study for the treatment of acute attacks of hereditary angioedema, and under Phase II proof study for the treatment of early antibody mediated rejection; Rifamycin SV MMX, a Phase III clinical program for the treatment of patients with travelersí diarrhea, as well as for other diseases with a bacterial component in the intestine; and SAN-300 under Phase I clinical study for the treatment of rheumatoid arthritis. The company was founded in 1996 and is based in San Diego, California.

Recent News: